<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863114</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.582</article-id><article-id pub-id-type="other">EPP0433</article-id><article-id pub-id-type="pii">S0924933824005820</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Association of anti-thyroid autoantibodies with neuropsychiatric features in patients with affective and schizophrenia spectrum disorders</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ilhan</surname><given-names>R. S.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0443" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Can</surname><given-names>K. C.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lalic</surname><given-names>S. N.</given-names></name><xref rid="aff1347" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Halaman</surname><given-names>E.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Aktay</surname><given-names>O.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>&#x000d6;zdemir</surname><given-names>F.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>&#x000c7;olak</surname><given-names>B.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Duman</surname><given-names>B.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yaz&#x00131;c&#x00131;</surname><given-names>S.</given-names></name><xref rid="aff1348" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Saka</surname><given-names>M. C.</given-names></name><xref rid="aff1346" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1346">
<sup>1</sup>Psychiatry, <institution>Ankara University</institution>, <city>ANKARA</city>, <country>T&#x000fc;rkiye</country>
</aff><aff id="aff1347">
<sup>2</sup>Psychiatry, Specil Psychiatric Hospital Department of Psychiatry Podvrsanska, psychiatry, <city>Vrsac</city>, <country>Serbia</country>
</aff><aff id="aff1348">
<sup>3</sup>Psychiatry, mamak devlet hastanesi, <city>ANKARA</city>, <country>T&#x000fc;rkiye</country>
</aff><author-notes><corresp id="cor0443">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="557">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S278</fpage><lpage>S279</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824005820a.pdf"/><abstract><sec id="sec2660"><title>Introduction</title><p>A growing body of evidence has shown the association between autoimmune thyroiditis and mental illness (Rege <italic toggle="yes">et al.</italic> AUS N J S Psychiatry 2013; 300 141-154). Identifying the neuropsychiatric features associated with thyroid antibody positivity could have significant implications for diagnostic and therapeutic strategies. However, the link between anti-thyroid antibodies and precise underlying pathophysiology requires future research.</p></sec><sec id="sec2661"><title>Objectives</title><p>
The aim of the present study was to conduct a retrospective evolution in patients diagnosed with schizophrenia spectrum disorder and affective disorder who were screened for anti-thyroid antibodies at the time of their hospitalization and to investigate neuropsychiatric features of anti-thyroid antibody-positive patients.</p></sec><sec id="sec2662"><title>Methods</title><p>
A total of 143&#x000a0;&#x000a0;inpatients diagnosed with schizophrenia spectrum disorders and affective disorders between 2021 and 2023 were screened for anti-thyroid antibodies such as thyroid peroxidase (TPO) and thyroglobulin (TG). All patients were women. In order to elucidate the subsequent neuropsychiatric clinical features of individuals with positive anti-thyroid antibodies, the retrospective examination was conducted based on Neuropsychiatric Invetory-Q (NPI-Q) and DSM-V diagnostic criteria utilized at the time of hospitalization.</p></sec><sec id="sec2663"><title>Results</title><p>
The main age of the patients was 48.2 (SD 10.4). A total of 143 inpatients with schizophrenia spectrum disorders and affective disorders were screened for anti-thyroid antibodies at the time of their hospitalizations. %23.1 (n=33) tested positive for at least one of the anti-TG or anti-TPO. All patients were euthyroid.&#x000a0;The neuropsychiatric diagnoses are shown in Table 1. The most common neuropsychiatric features assessed by&#x000a0;NPI-Q&#x000a0;are shown in Table 2. 12.1% (n=4) of all patients were treated with IV steroid Pulse therapy.<table-wrap position="anchor" id="tab16"><label>
Table 1.</label><caption><p>Neuropsychiatric&#x000a0;syndrom-level diagnostic patterns according to DSM-V</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Patients with positive thyroid autoantibodies<break/>(n=33)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Manic syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (30.3%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Psychotic Syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">19 ( 57.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Depression syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (15.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Catatonia</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (30.3%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Exited</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (18.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Stuporus</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (6.1%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Fluctuating</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (6.1%)</td></tr></tbody></table><graphic xlink:href="S0924933824005820-TABU0016" position="anchor"/></alternatives></table-wrap>
<table-wrap position="anchor" id="tab17"><label>
Table 2.</label><caption><p>The most common clusters of Neuropsychiatric features</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">NPI-Q
</th><th align="center" valign="middle" rowspan="1" colspan="1">Positive Thyroid Autoantibodies<break/>(n=33)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Delusion</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (45.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Agitation/Aggression</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (42.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Irr&#x00131;tability</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (42.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Motor abnormality</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (42.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sleep disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (45.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Appetite/Eating</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (42.4%)</td></tr></tbody></table><graphic xlink:href="S0924933824005820-TABU0017" position="anchor"/></alternatives></table-wrap>
</p></sec><sec id="sec2664"><title>Conclusions</title><p>In particular, in a subset of schizophrenia spectrum disorder or affective disorder patients with positive anti-thyroid antibodies may indicate autoimmunity, especially in cases where catatonic symptoms dominate the clinical presentation.</p></sec><sec id="sec2665"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>